Download PDF
Semin Liver Dis 2000; 20(2): 159-172
DOI: 10.1055/s-2000-9939
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Diagnostic Testing for Hepatitis C

Robert L. Carithers, Jr., Anthony Marquardt, David R. Gretch
  • University of Washington, Seattle, Washington
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

Diagnostic tests for hepatitis C virus have improved dramatically over the past decade. Highly accurate tests are now available for screening patients for possible hepatitis C infections and confirming the presence of active viral infection. HCV RNA levels and genotype are very useful in assessing the likelihood of response to antiviral therapy and in guiding the optimum duration of treatment. Absence of detectable HCV RNA using PCR methodology has become the gold standard of successful treatment of patients with chronic hepatitis C. The various tests for hepatitis C are expensive and have their limitations. However, selective use of these assays has greatly improved the care of patients with chronic hepatitis C.

KEYWORD

hepatitis C virus - diagnostic tests - HCV genotypes - HCV RNA - anti-viral therapy

REFERENCES

  • 1 McHutchison J G, Gordon S C, Schiff E R. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.  N Engl J Med . 1998;  339 1485-1492
    CrossrefPubMedGoogle Scholar
  • 2 Poynard T, Marcellin P, Lee S S. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).  Lancet . 1998;  352 1426-1432
    CrossrefPubMedGoogle Scholar
  • 3 Gretch D R. Diagnostic tests for hepatitis C.  Hepatology . 1997;  26(Suppl 1) 43S-47S
    CrossrefPubMedGoogle Scholar
  • 4 Gretch D R, Bacchi C E, Corey L. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features.  Hepatology . 1995;  22 1-9
    CrossrefPubMedGoogle Scholar
  • 5 Kao J-H, Lai M-Y, Hwang Y-T. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. A clinicopathologic study and demonstration of the usefulness of a third-generation assay.  Dig Dis Sci . 1996;  41 161-165
    PubMedGoogle Scholar
  • 6 Uyttendaele S, Claeys H, Mertens W, Verhaert H, Vermylen C. Evaluation of third-generation screening and confirmatory assays for HCV antibodies.  Vox Sang . 1994;  66 122-129
    CrossrefPubMedGoogle Scholar
  • 7 Barrera J, Prancis B, Ercilla G. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA.  Vox Sang . 1995;  68 15-18
    PubMedGoogle Scholar
  • 8 Pawlotsky J M, Lonjon I, Hezode C. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?.  Hepatology . 1998;  27 1700-1702
    CrossrefPubMedGoogle Scholar
  • 9 Morishima C, Gretch D R. Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy. In: Keefe EB, ed. Treatment of Chronic Hepatitis C Philadelphia: W.B. Saunders 1999: 717-740
    Google Scholar
  • 10 Atrah H I, Hutchinson F, Gough D, Ala F A. Hepatitis C seroconversion rate in established blood donors.  J Med Virol . 1995;  46 329-333
    PubMedGoogle Scholar
  • 11 Pawlotsky J M, Bastie A, Pellet C. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay.  J Clin Microbiol . 1996;  34 80-83
    PubMedGoogle Scholar
  • 12 Damen M, Zaaijer H L, Cuypers H T. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus.  Transfusion . 1995;  35 745-749
    CrossrefPubMedGoogle Scholar
  • 13 Younossi Z M, McHutchison J G. Serological tests for HCV infection.  Viral Hepatol Rev . 1996;  2 161-173
    PubMedGoogle Scholar
  • 14 Pawlotsky J M, Bastie A, Lonjon I. What technique should be used for routine detection and quantification of HBV DNA in clinical samples?.  J Virol Methods . 1997;  65 245-253
    CrossrefPubMedGoogle Scholar
  • 15 Fried M W. Clinical application of hepatitis C virus genotyping and quantitation. In: Davis GL, ed. Clinics in Liver Disease Philadelphia: W.B. Saunders 1997: 631-645
    Google Scholar
  • 16 Busch M P, Wilber J C, Johnson P, Tobler L, Evans C S. Impact of speciman handling and storage on detection of hepatitis C virus RNA.  Transfusion . 1992;  32 420-425
    CrossrefPubMedGoogle Scholar
  • 17 Davis G L, Lau J Y, Urdea M S. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: Definition of optimal conditions for specimen collection and clinical application in interferon-treated patients.  Hepatology. 1994;  19 1337-1341
    CrossrefPubMedGoogle Scholar
  • 18 Polyak S J, Gretch D R. Molecular diagnostic testing for viral hepatitis: Methods and applications. In: Willson RA, ed. Viral Hepatitis New York: Marcel Dekker 1997: 1-33
    Google Scholar
  • 19 Gretch D R, Wilson J J, Carithers Jr L R, dela Rosa C, Han J H, Corey L. Detection of hepatitis C virus RNA: Comparison of one-stage polymerase chain reaction (PCR) with nested-set PCR.  J Clin Microbiol. 1993;  31 289-291
    PubMedGoogle Scholar
  • 20 Kwok S, Higuchi R. Avoid false positives with PCR.  Nature . 1989;  339 237-238
    CrossrefPubMedGoogle Scholar
  • 21 Zaaijer H L, Cuypers H T, Reesink H W, Winkel I N, Gerken G, Lelie P N. Reliability of polymerase chain reaction for detection of hepatitis C virus.  Lancet . 1993;  341 722-724
    CrossrefPubMedGoogle Scholar
  • 22 Damen M, Cuypers H T, Zaaijer H L. International collaborative study on the second Eurohep HCV RNA reference panel.  J Virol Methods . 1996;  58 175-185
    CrossrefPubMedGoogle Scholar
  • 23 Saldanha J. Standardization, quantification and quality control of assays for HCV RNA.  Viral Hepatol Rev . 1999;  5 1-11
    PubMedGoogle Scholar
  • 24 Nolte F S, Thurmond C, Fried M W. Preclinical evaluation of AMPLICOR hepatitis C virus test for detection of hepatitis C virus RNA.  J Clin Microbiol . 1995;  33 1775-1778
    PubMedGoogle Scholar
  • 25 Young K K, Archer J J, Yokosuka O, Omata M, Resnick R M. Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: Comparison with nested amplification and antibody testing.  J Clin Microbiol . 1995;  33 654-657
    PubMedGoogle Scholar
  • 26 Zeuzem S, Ruster B, Roth W K. Clinical evaluation of a new polymerase chain reaction assay (AmplicorTM HCV) for detection of hepatitis C virus.  Z Gastroenterol . 1994;  32 342-347
    PubMedGoogle Scholar
  • 27 Albadalejo J, Alonso R, Antinozzi R. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C in the diagnostic laboratory.  J Clin Microbiol . 1998;  36 862-865
    PubMedGoogle Scholar
  • 28 Stapleton J T, Klinzman D, Schmidt W N. Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: Improved detection using whole blood as the source of viral RNA.  J Clin Microbiol . 1999;  37 484-489
    PubMedGoogle Scholar
  • 29 Schmidt W N, Wu P, Brashear D. Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells.  Hepatology . 1999;  28 1110-1116
    PubMedGoogle Scholar
  • 30 Lunel F, Cresta P, Vitour D. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays.  Hepatology . 1999;  29 528-535
    CrossrefPubMedGoogle Scholar
  • 31 Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche monitor assay, and an in-house limiting dilution method.  J Clin Microbiol . 1997;  35 187-192
    PubMedGoogle Scholar
  • 32 Reichard O, Norkrans G, Fryden A, Braconier J H, Sonnerborg A, Weiland O. Comparison of 3 quantitative HCV RNA assays-accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.  Scand J Infect Dis . 1998;  30 441-446
    PubMedGoogle Scholar
  • 33 Tong C Y, Hollingsworth R C, Williams H, Irving W L, Gilmore I T. Effect of genotypes on the quantification of hepatitis C virus (HCV) RNA in clinical samples using the Amplicor HCV Monitor test and the Quantiplex HCV RNA 2.0 assay (bDNA).  J Med Virol . 1998;  55 191-196
    CrossrefPubMedGoogle Scholar
  • 34 Gretch D R. Use and interpretation of HCV diagnostic tests in the clinical setting. In: Davis GL, ed. Clinic in Liver Disease Philadelphia: W.B. Saunders 1997: 543-557
    Google Scholar
  • 35 Gretch D R, dela Rosa C, Carithers Jr L R, Willson R A, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: Correlations and clinical implications.  Ann Intern Med . 1995;  123 321-329
    PubMedGoogle Scholar
  • 36 Pawlotsky J M, Martinot-Peignoux M, Poveda J D. Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays.  J Virol Methods . 1999;  79 227-235
    CrossrefPubMedGoogle Scholar
  • 37 Trabaud M A, Bailly F, Si-Ahmed S N. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon.  J Med Virol . 1997;  52 105-112
    CrossrefPubMedGoogle Scholar
  • 38 Bukh J, Miller R H, Purcell R H. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes.  Semin Liver Dis . 1995;  15 41-63
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Simmonds P, Holmes E C, Cha T A. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region.  J Gen Virol . 1993;  74 2391-2399
    PubMedGoogle Scholar
  • 40 Bukh J, Purcell R H, Miller R H. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide.  Proc Natl Acad Sci USA . 1993;  90 8234-8238
    PubMedGoogle Scholar
  • 41 Stuyver L, Van Arnhem W, Wyseur A, Hernandez F, Delaporte E, Maertens G. Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5B regions and identification of 5 additional subtypes.  Proc Natl Acad Sci USA . 1994;  91 10134-10138
    PubMedGoogle Scholar
  • 42 Okamoto H, Sugiyama Y, Okada S. Typing hepatitis C virus by polymerase chain reaction with type specific primers: Application to clinical surveys and tracing infectious sources.  J Gen Virol . 1992;  73 673-679
    PubMedGoogle Scholar
  • 43 Chayama K, Tsubota A, Arase Y. Genotype subtyping of hepatitis C virus.  J Gastroenterol Hepatol . 1993;  8 150-156
    PubMedGoogle Scholar
  • 44 Nakao T, Enomoto N, Takada N, Takada A, Date T. Typing of hepatitis C virus genomes by restriction fragment length polymorphism.  J Gen Virol . 1991;  72 2105-2112
    PubMedGoogle Scholar
  • 45 Simmonds P, McOmish F, Yap P L. Sequence variability in the 5′ non-coding region of hepatitis C virus: Identification of a new virus type and restrictions on sequence diversity.  J Gen Virol . 1993;  74 661-668
    PubMedGoogle Scholar
  • 46 Davidson F, Simmonds P, Ferguson J C. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′-non-coding region.  J Gen Virol . 1995;  76 1197-1204
    PubMedGoogle Scholar
  • 47 Mahaney K, Tedeschi V, Maertens G. Genotypic analysis of hepatitis C virus in American patients.  Hepatology . 1994;  20 1405-1411
    PubMedGoogle Scholar
  • 48 Lau J Y, Mizokami M, Kolberg J A. Application of six hepatitis C genotyping systems to sera from chronic hepatitis C patients in the United States.  J Infect Dis . 1995;  171 281-289
    PubMedGoogle Scholar
  • 49 Lau J YN, Davis G L, Prescott L E. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States.  Ann Intern Med . 1996;  124 868-876
    PubMedGoogle Scholar
  • 50 Simmonds P, Rose K A, Graham S. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.  J Clin Microbiol . 1993;  31 1493-1503
    PubMedGoogle Scholar
  • 51 Pawlotsky J M, Prescott L, Simmonds P. Serological determination of hepatitis C virus genotype: Comparison with a standardized genotyping assay.  J Clin Microbiol . 1997;  35 1734-1739
    PubMedGoogle Scholar
  • 52 Prescott L E, Berger A, Pawlotsky J M, Conjeevaram P, Pike I, Simmonds P. Sequence analysis of hepatitis C virus variants producing discrepant results with two different genotyping assays.  J Med Virol . 1997;  53 237-244
    CrossrefPubMedGoogle Scholar
  • 53 Hoofnagle J H. Hepatitis C: The clinical spectrum of disease.  Hepatology . 1997;  26(Suppl 1) 15S-20S
    CrossrefPubMedGoogle Scholar
  • 54 Alter M J, Margolis H S, Krawczynski K. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team.  N Engl J Med . 1992;  327 1899-1905
    CrossrefPubMedGoogle Scholar
  • 55 Farci P, Alter H J, Wong D. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis.  N Engl J Med . 1991;  325 98-104
    CrossrefPubMedGoogle Scholar
  • 56 Alter H J. Descartes before the horse: I clone, therefore I am. The hepatitis C virus in current perspective.  Ann Intern Med . 1991;  115 644-649
    PubMedGoogle Scholar
  • 57 McHutchison J G, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.  Semin Liver Dis . 1999;  19(Suppl 1) 57-65
    PubMedGoogle Scholar
  • 58 Davis G L, Lau J Y. Factors predictive of a beneficial response to therapy of hepatitis C.  Hepatology . 1997;  26(Suppl 1) 122S-127S
    CrossrefPubMedGoogle Scholar
  • 59 Barnes E, Webster G, Whalley S, Dusheiko G. Predictors of a favorable response to alpha interferon therapy for hepatitis C. In: Keefe EB, ed. Clinics in Liver Disease Philadelphia: W.B. Saunders 1999: 774-791
    Google Scholar
  • 60 Lindsay K L. Therapy of hepatitis C: Overview.  Hepatology . 1997;  26(Suppl 1) 71S-77S
    CrossrefPubMedGoogle Scholar
  • 61 Tong M J, Blatt L M, McHutchison J G, Co R L, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison.  Hepatology . 1997;  26 1640-1645
    PubMedGoogle Scholar
  • 62 Chemello L, Cavalleto L, Casarin C. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C.  Ann Intern Med . 1996;  124 1058-1060
    PubMedGoogle Scholar
  • 63 Marcellin P, Boyer N, Gervais A. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.  Ann Intern Med . 1997;  127 875-881
    PubMedGoogle Scholar
  • 64 Lau D-TY, Kleiner D E, Ghany M G, Park Y, Schmid P, Hoofnagle J H. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.  Hepatology . 1998;  28 1121-1127
    CrossrefPubMedGoogle Scholar
  • 65 Larghi A, Tagger A, Crosignani A. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy.  J Med Virol . 1998;  55 7-11
    CrossrefPubMedGoogle Scholar
  • 66 Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.  J Hepatol . 1999;  30 783-787
    CrossrefPubMedGoogle Scholar
  • 67 Vento S, Concia E, Ferraro T. Lack of sustained efficacy of interferon in patients with chronic hepatitis C.  N Engl J Med . 1996;  334 1479-1480
    CrossrefPubMedGoogle Scholar
  • 68 National Institutes of Health Consensus Development Conference Panel statement. Management of hepatitis C.  Hepatology . 1997;  26(Suppl 1) 2S-10S
    CrossrefPubMedGoogle Scholar
  • 69 Alberti A, Chemello L, Noventa F, Cavalletto L, De S G. Therapy of hepatitis C: Retreatment with alpha interferon.  Hepatology . 1997;  26(Suppl 1) 137S-142S
    CrossrefPubMedGoogle Scholar
  • 70 Chemello L, Cavalletto L, Donada C. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.  Gastroenterology . 1997;  113 1654-1659
    PubMedGoogle Scholar
  • 71 Camma C, Giunta M, Chemello L. Chronic hepatitis C: Interferon retreatment of relapsers. A meta- analysis of individual patient data.  Hepatology . 1999;  30 801-807
    CrossrefPubMedGoogle Scholar
  • 72 Davis G L, Esteban-Mur R, Rustgi V. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.  N Engl J Med . 1998;  339 1493-1499
    CrossrefPubMedGoogle Scholar
  • 73 Davis G L. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.  Semin Liver Dis . 1999;  19(Suppl 1) 49-55
    PubMedGoogle Scholar
  • 74 Heathcote E J, Keeffe E B, Lee S S. Retreatment of chronic hepatitis C with consensus interferon.  Hepatology . 1998;  27 1136-1143
    CrossrefPubMedGoogle Scholar
  • 75 Barbaro G, Di Lorenzo G, Belloni G. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial.  Am J Med . 1999;  107 112-118
    CrossrefPubMedGoogle Scholar
  • 76 Schreiber G B, Busch M P, Kleinman S H, Korelitz J J. The risk of transfusion-transmitted viral infections.  N Engl J Med . 1996;  334 1685-1690
    CrossrefPubMedGoogle Scholar
  • 77 Vrielink H, Zaaijer H L, Reesink H W, van der Poel L C, Cuypers H T, Lelie P N. Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs.  Vox Sang . 1995;  69 14-17
    PubMedGoogle Scholar
  • 78 Terrault N A, Wright T L, Pereira B JG. Hepatitis C infection in the transplant recipient.  Infect Dis Clin North Am . 1995;  9 943-964
    PubMedGoogle Scholar
  • 79 Roth D. Hepatitis C virus: The nephrologist's view.  Am J Kidney Dis . 1995;  25 3-16
    PubMedGoogle Scholar
  • 80 Tokars J I, Alter M J, Favero M S, Moyer L A, Miller E, Bland L A. National surveillance of dialysis associated diseases in the United States, 1993.  ASAIO J . 1996;  42 219-229
    PubMedGoogle Scholar
  • 81 Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease.  MMWR Morb Mortal Wkly Rep . 1998;  47 1-39
    PubMedGoogle Scholar
  • 82 Chan T M, Lok A SF, Cheng I KP, Chan R T. Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assays.  Hepatology . 1993;  17 5-8
    CrossrefPubMedGoogle Scholar
  • 83 Fabrizi F, Lunghi G, Andrulli S. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients.  Nephrol Dial Transplant . 1997;  12 1394-1398
    PubMedGoogle Scholar
  • 84 Couroucé A M, Bouchardeau F, Chauveau P. Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays).  Nephrol Dial Transplant . 1995;  10 234-239
    PubMedGoogle Scholar
  • 85 Strasser S I, Myerson D, Spurgeon C L. Hepatitis C virus infection and bone marrow transplantation: A cohort study with 10-year follow-up.  Hepatology . 1999;  29 1893-1899
    CrossrefPubMedGoogle Scholar
  • 86 Strasser S I, Sullivan K M, Myerson D. Cirrhosis of the liver in long-term marrow transplant survivors.  Blood . 1999;  93 3259-3266
    PubMedGoogle Scholar
  • 87 Hsu H H, Wright T L, Tsao S C. Antibody response to hepatitis C virus after liver transplantation.  Am J Gastroenterol . 1994;  89 1169-1174
    PubMedGoogle Scholar
  • 88 Lok A S, Chien D, Choo Q L. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients.  Hepatology . 1993;  18 497-502
    CrossrefPubMedGoogle Scholar
  • 89 Feray C, Gigou M, Samuel D. The course of hepatitis C virus infection after liver transplantation.  Hepatology . 1994;  20 1137-1143
    CrossrefPubMedGoogle Scholar
  • 90 Wright T L, Donegan E, Hsu H H. Recurrent and acquired hepatitis C viral infection in liver transplant recipients.  Gastroenterology . 1992;  102 317-322
    PubMedGoogle Scholar
  • 91 Chamot E, Hirschel B, Wintsch J. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users.  AIDS . 1990;  4 1275-1277
    PubMedGoogle Scholar
  • 92 Vogt M, Lang T, Frosner G. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.  N Engl J Med . 1999;  341 866-870
    CrossrefPubMedGoogle Scholar
  • 93 Ohto H, Terazawa S, Sasaki N. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group.  N Engl J Med . 1994;  330 744-750
    CrossrefPubMedGoogle Scholar
  • 94 Giacchino R, Tasso L, Timitilli A. Vertical transmission of hepatitis C virus infection: Usefulness of viremia detection in HIV-seronegative hepatitis C virus-seropositive mothers.  J Pediatr . 1998;  132 167-169
    PubMedGoogle Scholar
  • 95 Jonas M M. Hepatitis C infection in children.  N Engl J Med . 1999;  341 912-913
    PubMedGoogle Scholar
      >